S
ALXN

Seeyond’s Alexion Pharmaceuticals ALXN Stock Holding History

Seeyond’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,538
Closed -$1.75M – 614
2021
Q2 		$1.75M Buy
9,538
+42
+0.4% +$7.21K 0.16% 208
2021
Q1 		$1.45M Buy
9,496
+8,661
+1,037% +$1.34M 0.15% 230
2020
Q4 		$130K Sell
835
-23,913
-97% -$3.07M 0.01% 587
2020
Q3 		$2.83M Buy
24,748
+5,655
+30% +$610K 0.31% 70
2020
Q2 		$2.14M Buy
19,093
+15,859
+490% +$1.68M 0.24% 104
2020
Q1 		$749K Sell
3,234
-24
-0.7% -$2.35K 0.1% 282
2019
Q4 		$352K Hold
3,258
– – 0.04% 481
2019
Q3 		$319K Sell
3,258
-1,114
-25% -$126K 0.03% 477
2019
Q2 		$573K Buy
4,372
+1,574
+56% +$203K 0.06% 438
2019
Q1 		$378K Hold
2,798
– – 0.04% 490
2018
Q4 		$272K Buy
+2,798
New +$331K 0.04% 466

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Seeyond's ALXN Position: Q3 2021 in Review

Seeyond sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 9,538 shares — an estimated $1.75M sold.

Seeyond first reported a position in ALXN in Q4 2018 and held it in 11 quarters. The position peaked at $2.83M in Q3 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Seeyond reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Seeyond sold 9,538 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.75M.
  • Seeyond first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 11 quarters.
  • Seeyond's Alexion Pharmaceuticals position peaked at $2.83M in Q3 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Seeyond's 13F filing for Q3 2021, filed 12 Nov 2021.